Other neoplams 152-152.9, 160-160.9,164-164.9, 170-171.9, 181-181.9, 182.9, 183.2-183.8, 184.0-184.4, 184.8, 187.1-187.8, 189.2-189.8, 190-190.9, 194-194.8 C17-C17.9, C30-C31.9, C37-C38.8, C40-C41.9, C47-C49.9, C50.12-C50.129, C51-C52.9, C57-C57.8, C58, C58.0, C60-C60.9, C63-C63.8, C66-C66.9, C68.0-C68.8, C69-C69.92, C74-C75.8
Other benign neoplasm 209.4, 209.40, 209.41, 209.42, 209.43, 211.2, 211.8, 212.0, 212.4, 212.5, 212.6, 212.7, 212.8, 213, 213.0, 213.1, 213.2, 213.3, 213.4, 213.5, 213.6, 213.7, 213.8, 213.9, 214.2, 214.3, 214.4, 214.8, 214.9, 221.0, 221.1, 221.2, 221.8, 222.1, 222.8, 223.2, 223.8, 223.81, 223.89, 224, 224.0, 224.1, 224.2, 224.3, 224.4, 224.5, 224.6, 224.7, 224.8, 224.9, 227, 227.0, 227.1, 227.3, 227.4, 227.5, 227.6, 227.8, 227.9, 228, 228.0, 228.00, 228.01, 228.02, 228.03, 228.04, 228.09, 228.1, 228.9, 229.0, 229.8, 230.7, 230.8, 233.31, 233.32, 233.4, 233.5, 234.0, 234.5, 234.8, 235.4, 235.8, 236.1, 236.99, 238.0, 238.1, 238.4, 238.5, 238.6, 238.7, 238.71, 238.72, 238.73, 238.74, 238.75, 238.76, 238.77, 238.79, 238.8, 239.2, 623.0, 623.1, 623.7, 210 
Search Query Items

#1
( TITLE-ABS-KEY ( "Anorexia nervosa" OR "eating disorder*" ) ) AND ( TITLE-ABS-KEY ( cancer* OR carcinoma* OR neoplasia* OR tumor* OR neoplasm* OR mali gna* ) ) AND ( TITLE-ABS-KEY ( epidemiolog* OR cohort* OR "longitudinal stud*" OR "case-control" ) )
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eTable 3c. Key terms for Embase search.
Search Query Items
#1
'anorexia nervosa':ti,ab,kw OR 'eating disorder':ti,ab,kw AND ('maligna*':ti,ab,kw OR 'neoplasm*':ti,ab,kw OR 'neoplasia*':ti,ab,kw OR 'tumor*':ti,ab,kw OR 'cancer*':ti,ab,kw OR 'carcinoma*':ti,ab,kw) AND ('epidemiolog*':ti,ab,kw OR 'cohort*':ti,ab,kw OR 'longitudinal stud*':ti,ab,kw OR 'case-control':ti,ab,kw) 38 eTable 3d. Key terms for Web of Science Core collection search.
Search Query Items #1 TS=( "Anorexia nervosa" OR "eating disorder*" ) AND TS=( cancer* OR carcinoma* OR neoplasia* OR tumor* OR neoplasm* OR maligna* ) AND TS=( epidemiolog* OR cohort* OR "longitudinal stud*" OR "case-control" ) Índices=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Período de tiempo=Todos los años 85 Research (AICR) criteria and GRADE system emphasize certainty (or credibility) of evidence based on randomized controlled data. For many risks in the biomedical literature (such as disease comorbidity), we will never have randomized controlled trials, and to restrict the assessment of exposures (or risks factors) to only those with trial evidence would lead us to ignore some of the most important determinants of health. Randomized controlled trials are unavailable for our research question. It is for this reason that we have used modified criteria of "convincing/high certainty" or "probable/moderate certainty" evidence for causality. If well designed and reported observational cohort studies form the evidence base the certainty rating starts with high/convincing evidence. If well designed and reported case-control studies form the evidence base the rating starts with moderate/probable evidence. Because the GRADE system does not yet have a scale for assessing non-interventional observational studies, we used a modified version to describe the validity and trustability of the evidence we presented in each meta-analysis. In brief, we rated the evidence as "convincing or high" when we are highly confident that the true effect lies close to that estimated. For example, evidence is judged as "convincing or high" if all of the following apply:
• There are multiple cohort studies included in the analyses with no major limitations (low risk of bias according to NOS scale) • Summary effect estimate P value < 10 -6
• The is little variation between studies (I 2 < 50%) • The summary estimate has a narrow confidence interval (95% predictive interval excluding null value) We rated the evidence as "probable or moderate" when we consider the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. For example, evidence might be judged as "probable or moderate" if any of the following applies:
• There are only few studies and some have limitations but not major flaws (low/moderate risk of bias according to NOS scale) • Summary effect estimate P value < 10 -3
• There is some variation between studies (I 2 = 50-70%) • The 95% predictive interval is wide Finally, we rated the evidence to be "low (limited, not conclusive or unlikely)" when the true effect may be substantillay different from the estimate of its effect. "Low/limited-suggestive evidence" represents too limited evidence to conclude on a probable or convincing causal association, but where there is evidence suggestive of a direction of effect. "Low/limited-not conclusive evidence" consists of information that is so limited that no firm conclusion can be made for several reasons (e.g., the evidence might be limited by the amount of evidence in terms of the number of studies available, by inconsistency of direction of effect, by poor quality of studies, or by any combination of these factors). For example, evidence might be judged as "low quality" if any of the following apply:
• There is only one study or studies have major methological flaws (high risk of bias according to NOS scale) • Summary effect estimate P value < 0.05 • There is important variation between study results (I 2 > 70%) • The confidence interval of the summary estimate of the effect is very wide (95% predictive interval including null value or 95% predictive interval was inestimable e.g. less than 3 studies) • Small study effects (sometimes called "publication bias") Certainty of the evidence and reasons for each outcome of interest.
Outcomes of interest
Certainty of the evidence and reason Primary outcome of all cancer All cancer, incidence both sexes ⃝ ⃝ Low confidence (risk unlikely) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable All cancer, incidence women ⃝ ⃝ ⃝ Moderate confidence (risk unlikely) Downgraded: (-1) 95% prediction interval wide All cancer, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable All cancer, mortality both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable All cancer, mortality women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Secondary outcome of sitespecific cancer Bladder and urinary, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Bone and articular cartilage, mortality women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Brain and central nervous system, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Brain and central nervous system, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-2) 95% prediction interval very wide Brain and central nervous system, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Breast, incidence women ⃝ ⃝ ⃝ ⃝ High confidence (convincing) Breast, mortality women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Cervix, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Colon and rectum, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Colon and rectum, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Colon and rectum, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Esophagus, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Esophagus, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Gallbladder, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Kidney, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Kidney, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Kidney, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Lip and oral cavity, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Liver, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Lung, incidence both sexes ⃝ ⃝ Low confidence (limited-suggestive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Lung, incidence women ⃝ ⃝ Low confidence (limited-suggestive) Downgraded: (-2) 95% prediction interval very wide Lung, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Lung, mortality women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Lymphoid and hematopoietic, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Lymphoid and hematopoietic, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-2) 95% prediction interval very wide Lymphoid and hematopoietic, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Lymphoid and hematopoietic, mortality women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Malignant skin melanoma, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Malignant skin melanoma, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-2) 95% prediction interval very wide Malignant skin melanoma, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Malignant skin melanoma, mortality women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Other skin cancer, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Other skin cancer, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Other skin cancer, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Ovary, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Pancreas, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Pancreas, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Pancreas, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Prostate, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Stomach, incidence both sexes ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Stomach, incidence women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only few studies (n=2), (-1) 95% prediction interval inestimable Stomach, mortality women ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable Testicular, incidence men ⃝ ⃝ Low confidence (limited-not conclusive) Downgraded: (-1) only one study, (-1) 95% prediction interval inestimable 
Random-effects meta-analysis
Heterogeneity: I 2 = 0.0%, p = 0.66
Breast, mortality women
Karaminis 2014 Mellemkjaer 2015 Random-effects meta-analysis 
All cancer, mortality both
Korndörfer 2003 Subtotal (I-squared = .%, p = .)
All cancer, incidence women
Michels 2004
Mellemkjaer 2015
Subtotal (I-squared = 0.0%, p = 0.729)
All cancer, incidence both
Mellemkjaer 2015 Subtotal (I-squared = .%, p = .)
All cancer, incidence men
Mellemkjaer 2015 Subtotal (I-squared = .%, p = .) 
